Tobevibart

- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with late-line metastatic prostate cancer - Company will present complete Week 96 Phase 2 SOLSTICE data on its combination regimen for chronic hepatitis delta (CHD) at the European Association for the Study of the Liver (EASL) Congress - Strong financial position with $809.3 million in cash and investments as of March 31, 2026, excluding $315 million combined Astellas upfront payment1 and equity investment to be received in the second quarter of 2026 - Conference call scheduled for May 6, 2026, at 4:30 p.m. ET / 1:30 p.m. PT SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of our collaboration with Astellas in April has ignited the next stage of development work, bolstering our ability to move faster and think bigger together,” said Marianne De Backer, Chief Executive Officer of Vir Biotechnology. “We also announced promising updated Phase 2 data on our combination regimen in CHD and will be presenting complete Week 96 data at the EASL Congress later this month. CHD is the most severe form of hepatitis. We believe our well-tolerated combination regimen is uniquely positioned to change the standard of care, bringing together robust efficacy with the potential for self-administration at home with once monthly subcutaneous dosing.” Pipeline Programs Chronic Hepatitis Delta (CHD) The Company will present additional data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for CHD at the EASL Congress taking place May 27-30, 2026. Earlier this year, the Company reported Phase 2 SOLSTICE data showing that the monthly combination of tobevibart and elebsiran was highly efficacious and well-tolerated. Undetectable hepatitis delta virus RNA (HDV RNA Target Not Detected, TND) was achieved and maintained by 77% (24/31) of participants receiving the combination regimen at Week 72. This rate increased to 88% (21/24) in the subset of participants evaluated through Week 96. Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026. Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027. Solid Tumors VIR-5500 The Company closed its global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN ® dual-masked TCE VIR-5500 for the treatment of prostate cancer. The first patient was dosed in the Phase 1 dose-expansion cohorts evaluating the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in prostate cancer. The first expansion cohort will evaluate VIR-5500 monotherapy in Q3W 800/2000/3500 µg/kg step-up dosing in late-line metastatic castration-resistant prostate cancer (mCRPC). The Company anticipates initiating pivotal Phase 3 trials in 2027. Positive updated Phase 1 data for VIR-5500 monotherapy showed dose-dependent anti-tumor activity and a well-tolerated safety profile in patients with mCRPC. The data were presented in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. VIR-5818 Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN ® dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026. VIR-5525 The Phase 1 study of VIR-5525, an EGFR-targeted PRO-XTEN ® dual-masked TCE, continues enrollment as expected. Preclinical Pipeline Candidates The Company is currently progressing a number of PRO-XTEN ® masked TCEs in preclinical studies directed at clinically validated targets with potential applications across a variety of solid tumors, including lung, colorectal and bladder. Corporate Update The Company completed a follow-on public offering of common stock with gross proceeds of $172.5 million, before deducting underwriting discounts and commissions and offering expenses. First Quarter 2026 Financial Results Cash, Cash Equivalents and Investments: As of March 31, 2026, the Company had $809.3 million in cash, cash equivalents and investments, representing an increase of approximately $27.7 million during the first quarter of 2026. During the first quarter of 2026, the Company completed a public offering of its common stock with gross proceeds of $172.5 million, before deducting underwriting discounts and commissions and offering expenses. Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2026 were $108.9 million, which included $6.0 million of non-cash stock-based compensation expense, compared to $118.6 million for the same period in 2025, which included $7.0 million of non-cash stock-based compensation expense. The decrease was primarily driven by a $30.0 million expense in the first quarter of 2025 in connection with signing the restated Alnylam agreement, partially offset by higher CHD contract manufacturing costs associated with process performance qualification batches in preparation for commercialization, and to a lesser extent, higher clinical expenses from the progression of both our CHD and oncology programs in the first quarter of 2026. Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the first quarter of 2026 were $23.3 million, which included $6.1 million of non-cash stock-based compensation expense, compared to $23.9 million for the same period in 2025, which included $7.1 million of non-cash stock-based compensation expense. Net Loss: Net loss for the first quarter of 2026 was $125.7 million, or $0.85 per share, basic and diluted, compared to a net loss of $121.0 million, or $0.88 per share, basic and diluted for the same period in 2025. 2026 Financial Guidance Based on our current operating plans, including the net effects of the Astellas global collaboration, the Astellas equity investment and the completion of the recent equity financing, the Company expects its cash, cash equivalents and investments to fund operations into the second half of 2028. Conference Call Vir Biotechnology will host its first quarter 2026 financial results conference call at 4:30 p.m. ET / 1:30 p.m. PT today. A live webcast will be available at https://investors.vir.bio and will be archived for 30 days. About the ECLIPSE Registrational Program ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE includes three randomized, controlled trials designed to evaluate the combination therapy in comparison to deferred treatment or bulevirtide. ECLIPSE 1 (NCT06903338) is a Phase 3 trial evaluating the safety and efficacy of tobevibart in combination with elebsiran compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited. ECLIPSE 2 (NCT07128550) is a Phase 3 trial evaluating the efficacy and safety of switching to tobevibart and elebsiran in people with CHD who have not achieved viral suppression with bulevirtide therapy. ECLIPSE 1 and 2 are designed to provide the registrational efficacy and safety data needed for potential submission to global regulatory agencies. ECLIPSE 3 (NCT07142811) is a Phase 2b head-to-head trial evaluating combination tobevibart and elebsiran compared with bulevirtide in bulevirtide-naïve patients, and it is designed to provide important supportive data to help establish access and reimbursement in key markets. About Tobevibart and Elebsiran Tobevibart is an investigational broadly neutralizing monoclonal antibody (mAb) targeting the hepatitis B surface antigen (HBsAg). It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology’s proprietary mAb discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor’s Xtend™ technology to extend half-life. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) licensed from Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of HBsAg. Current data indicate that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta. About Chronic Hepatitis Delta (CHD) CHD is the most severe form of chronic viral hepatitis2 and was recently classified as carcinogenic by the International Agency for Research on Cancer.3 People living with the disease rapidly progress to cirrhosis, liver failure4 and liver-related death.2 There are currently no approved treatments in the U.S., and options are limited in the European Union and globally. About VIR-5500, VIR-5818 and VIR-5525 VIR-5500, VIR-5818 and VIR-5525 are investigational, clinical candidates currently being evaluated for the treatment of solid tumors. These assets leverage the universal PRO-XTEN® masking technology and target PSMA, HER2 and EGFR, respectively. TCEs are powerful anti-tumor agents that can direct the immune system, specifically T-cells, to destroy cancer cells. The universal PRO-XTEN® masking technology is designed to keep the TCEs inactive (or masked) until they reach the tumor microenvironment, where tumor-specific proteases cleave off the mask and activate the TCEs, leading to killing of cancer cells by T-cells. By confining the activity to the tumor microenvironment, we aim to circumvent the traditionally high toxicity associated with TCEs and increase their efficacy and tolerability. Additionally, the mask is designed to help drug candidates stay in the bloodstream longer in their inactive form, allowing them to better reach the site of action and potentially allowing less frequent dosing regimens for patients and clinicians. About Advanced Prostate Cancer Prostate cancer remains a significant global health burden, representing the second leading cause of cancer-related mortality in men behind lung cancer.5 While diagnostic and therapeutic advances like androgen-directed therapy can improve outcomes in earlier settings, most patients ultimately relapse and develop metastatic hormone sensitive prostate cancer (mHSPC).6 mHSPC is characterized by its responsiveness to intensified hormonal interventions designed to reduce androgen levels or block their action. The majority of these patients eventually progress to metastatic castration-resistant prostate cancer (mCRPC).7 This stage is associated with poor clinical outcomes, including limited durability of existing therapies, with a 5-year survival rate of approximately 30%.8 There is a critical need for safer, more effective, and precisely targeted therapies capable of improving long term disease control and quality of life across the prostate cancer continuum. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes and references: 1 Under the terms of Vir Biotechnology's licensing agreement with Sanofi, we will share with Sanofi 20% of certain future collaboration proceeds from the Astellas collaboration agreement. 2 National Institute of Diabetes and Digestive and Kidney Diseases. Hepatitis D. NIDDK. Published November 2024. Accessed September 2025. Hepatitis D - NIDDK (nih.gov). 3 Karagas, Margaret R et al., “Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus” The Lancet Oncology, vol. 26, no. 8 (2025): 994 – 995. doi: 10.1016/S1470-2045(25)00403-6. 4 Center for Disease Control and Prevention. Hepatitis D FAQs. CDC. Published March 2020. Accessed September 2025. What is Hepatitis D - FAQ | CDC. 5 Kratzer TB, et. al. “Prostate cancer statistics, 2025.” CA Cancer J Clin. vol. 75 no. 6 (2025): 485-497. doi:10.3322/caac.70028. 6 Bernard-Terrier A & Beltran H. “Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine.” J Clin Invest. vol. 136 no. 3 (2026):e200920. doi: 10.1172/JCI200920. 7 Leith A, et. al. “Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.” Adv Ther. vol. 39 (2022): 2236-2255. doi: 10.1007/s12325-022-02073-w. 8 Huo, X et al. “Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram.” Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: Vir Biotechnology’s cash balance and anticipated runway; Vir Biotechnology’s collaboration with Astellas, including potential payments to be made to Vir Biotechnology under such collaboration; Vir Biotechnology’s future financial and operating results and its expectations related thereto, including Vir Biotechnology’s financial guidance; the therapeutic and commercial potential of Vir Biotechnology's CHD program, as well as Vir Biotechnology's strategy, plans and expectations related thereto; the therapeutic and commercial potential of VIR-5500 and the other assets in Vir Biotechnology's oncology solid tumor clinical portfolio, preclinical pipeline and the PRO-XTEN® masking technology, as well as Vir Biotechnology's strategy, plans and expectations related thereto; the potential of and Vir Biotechnology’s expectations for its other pipeline programs; Vir Biotechnology’s plans and expectations for its clinical development programs, including protocols for and enrollment into ongoing and planned clinical studies, potential partnering opportunities, and data readouts and presentations, as well as anticipated timelines; the potential benefits, safety and efficacy of Vir Biotechnology’s investigational therapies; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; the timing and amount of Vir Biotechnology’s actual operating expenses, as determined in accordance with U.S. Generally Accepted Accounting Principles; difficulties in collaborating with other companies, some of whom may be competitors of Vir Biotechnology or otherwise have divergent interests, and uncertainty as to whether the benefits of Vir Biotechnology’s various collaborations can ultimately be achieved in the amounts and on the timeline Vir Biotechnology expects; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology’s planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology’s competitors, as well as changes in expected or existing competition; Vir Biotechnology’s use of AI and machine learning in its efforts to engineer next-generation proteins and in other research and development efforts; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later-stage or larger-scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. VIR BIOTECHNOLOGY, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) March 31, 2026 December 31, 2025 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 274,161 $ 232,185 Short-term investments 196,277 228,753 Restricted cash and cash equivalents, current 1,925 1,922 Equity investments 5,861 6,077 Prepaid expenses and other current assets 44,761 45,143 Total current assets 522,985 514,080 Intangible assets, net 7,777 7,850 Goodwill 16,937 16,937 Property and equipment, net 53,158 55,620 Operating right-of-use assets 60,760 62,099 Restricted cash and cash equivalents, noncurrent 6,956 6,963 Long-term investments 332,970 314,575 Other assets 24,042 24,699 TOTAL ASSETS $ 1,025,585 $ 1,002,823 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 5,445 $ 9,803 Accrued and other liabilities 68,113 83,012 Total current liabilities 73,558 92,815 Operating lease liabilities, noncurrent 86,635 89,054 Contingent consideration obligation, noncurrent 33,210 34,100 Other long-term liabilities 19,417 21,578 TOTAL LIABILITIES 212,820 237,547 Commitments and contingencies (Note 7) STOCKHOLDERS’ EQUITY: Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 — — Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 161,234,058 and 139,474,954 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 16 14 Additional paid-in capital 2,139,698 1,965,090 Accumulated other comprehensive loss (3,483 ) (2,057 ) Accumulated deficit (1,323,466 ) (1,197,771 ) TOTAL STOCKHOLDERS’ EQUITY 812,765 765,276 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 1,025,585 $ 1,002,823 VIR BIOTECHNOLOGY, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, 2026 2025 Revenues: License and collaboration revenue $ (41 ) $ (70 ) Grant revenue 12 1,238 Other revenue — 1,864 Total revenues (29 ) 3,032 Operating expenses: Research and development 108,922 118,645 Selling, general and administrative 23,339 23,944 Restructuring, long-lived assets impairment and related charges, net — (10 ) Total operating expenses 132,261 142,579 Loss from operations (132,290 ) (139,547 ) Other income: Change in fair value of equity investments (170 ) 6,382 Interest income 7,189 12,288 Other expense, net (254 ) (72 ) Total other income 6,765 18,598 Loss before provision for income taxes (125,525 ) (120,949 ) Provision for income taxes (170 ) (16 ) Net loss $ (125,695 ) $ (120,965 ) Net loss per share, basic and diluted $ (0.85 ) $ (0.88 ) Weighted-average shares outstanding, basic and diluted 147,356,811 137,468,900 Media Contact Caren Scannell Director, Communications cscannell@vir.bio Investor Contact Kiki Patel, PharmD Head of Investor Relations kpatel@vir.bio

→ Ex- Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer , but he will be a senior strategic advisor to CEO Albert Bourla . BMO Capital Markets broke the news in a Monday note. Baum came to Pfizer in June 2024 as the pharma giant grappled with its post-Covid future and watched its shares lose more than half their value from the previous year. There has been an incremental year-to-date recovery, but we’re far from the days of the Covid boom. In a statement sent to Endpoints News , Pfizer said it has initiated a reorg within the strategy and business innovation team “to position Pfizer to move faster, make clearer decisions, and advance innovation across the enterprise.” Pfizer did win a crucial battle in the obesity space last fall by thwarting Novo Nordisk and buying Metsera . → In a rapid change of heart that came at the direction of the board, Michael Cola was asked to step down immediately as CEO of Helus Pharma , the company announced this week. Cola joined in February and replaced Doug Drysdale , who had led the company (formerly known as Cybin ) for more than five years. He’ll be replaced on an interim basis by executive chairman Eric So , who also temporarily led the company after Drysdale stepped down in September 2025. Cola was meant to add large pharma experience at a critical moment, as Helus advances its psilocybin analog through a Phase 3 trial with a key readout that’s expected before the end of the year. Despite not having the same name recognition as some of the other psychedelic companies, Helus is one of the closest to potential FDA filing. Cola was previously president of Shire ’s specialty pharma business, with earlier stints at AstraZeneca . He was also the CEO of Avalo Therapeutics . Before the week ended, Helus appointed Moderna co-founder Bob Langer and former Karuna Pharmaceuticals CMO Stephen Brannan to its scientific advisory board. → BioMarin chairman Randy Meier is retiring, and ex- Genentech CEO Ian Clark is slated to take over once stockholders have their say at the company’s annual meeting in June. CEO Alexander Hardy — who also once led Genentech — said in a statement that Meier “has helped guide BioMarin through a period of meaningful growth and transformation” throughout his 20-year tenure on the board. Meier succeeded Jean-Jacques Bienaimé as chairman in 2023, while Clark joined the board last summer. The move comes after BioMarin pulled the plug on its $2.9 million gene therapy Roctavian . → There will be a changing of the guard at Chiesi as group CEO Giuseppe Accogli departs on May 15. Group CFO Jean-Marc Bellemin will fill in as interim chief until a successor is named at the Italian pharma. Accogli had a 16-year career at Baxter before he succeeded Ugo Di Francesco in 2023. Chiesi is taking a dip into CRISPR through a deal with Arbor Biotechnologies that could be worth up to $2 billion. The partnership focuses on licensing and developing Arbor’s gene editing therapy for primary hyperoxaluria type 1 called ABO-101 . Chinese biotech YolTech Therapeutics is also testing a CRISPR therapy for this rare genetic condition. → Former Aragon and Seragon leader Rich Heyman has decided to retire as chairman of p53 drug developer PMV Pharmaceuticals , and he’ll replaced by Laurie Stelzer . For nine months in 2025, Stelzer held the CFO post at obesity biotech Kailera Therapeutics , which just put together a record IPO last week. She has a history of CFO stints at biotechs that become M&A bait: Arena Pharmaceuticals ( bought by Pfizer); Mirati Therapeutics ( bought by Bristol Myers Squibb ); and Orna Therapeutics ( bought by Eli Lilly ). Stelzer is a board member at Sionna Therapeutics , Spyre Therapeutics and MBX Biosciences . → The allure of T cell engagers, one of the hottest modalities in biotech startup funding and pharma dealmaking, has caught Luis Borges . After four CSO posts since 2017, Borges is now tackling the duties of CEO at a Philadelphia biotech that he’s founded. Artemia Therapeutics appears to be only a few months old, according to Borges’ LinkedIn, and is currently seeking seed funding. “Artemia is built on a simple but powerful premise: to translate the clinical validation seen with cellular therapies into a more scalable, practical, and broadly accessible biologics modality,” he wrote in a LinkedIn post . Borges recently departed the CSO post at US and Japan cell therapy outfit Shinobi Therapeutics . Metagenomi , Century Therapeutics and Cell Medica have also relied on Borges for CSO responsibilities over the past decade. → Santhera CEO Dario Eklund is headed for the exit, and the Swiss biotech has already lined up Orlando Oliveira as his successor. Oliveira is scheduled to begin July 15 and has been chief commercial officer for Lonnie Moulder ’s crew at Zenas BioPharma for nearly two years. He was also head of international for Mirati Therapeutics from 2022-24. “After almost seven years in this role, I believe the time is right for a planned leadership transition,” Eklund said in a statement . “I have long believed that leadership renewal, at the right time, is healthy for companies — bringing fresh perspectives, renewed energy and support for the next phase of growth.” → Alicia Secor has flown into the bat cave. She’s taken on the CEO role at Paratus Sciences , which Polaris Partners and ARCH believe can turn bat biology into a launchpad for new medicines. When Theresa Heah stepped into the CEO post at Paratus two years ago, she caught our attention by saying she wished she were a bat because of the power of bat biology. The ability to manage inflammation, have longer health spans and other qualities were quite appealing. Heah has since gone on to lead ophthalmology group Eyexora , and her successor arrives after a brief break from the chief executive seat. Secor led RNAi startup Atalanta Therapeutics toward the clinic. For five years, she navigated the biotech-building process with one investor. Then, at the beginning of 2025, she secured the help of multiple investors in a $97 million Series B . And she’s bringing the CFO who helped engineer that financing with her. Jeffrey Young will take on the same duties at Paratus as the Boston and Singapore biotech gears up for the clinic with a pan-inflammasome inhibitor called PS-1001 . Ganesh Mugundu is also joining Paratus as head of clinical development. → Vir Biotechnology medical chief Mark Eisner has called it quits, according to an SEC filing . Eisner succeeded Phil Pang on June 3, 2024, and only lasted nine months in the same position at Sonoma Biotherapeutics . He spoke to Endpoints in November about the “very, very strong antiviral efficacy” that was seen in the mid-stage data for Vir’s hepatitis D combo regimen of tobevibart and elebsiran . → Ruxandra Draghia Akli left her role as Novavax ’s head of R&D earlier this month after about a year and a half, pursuing other opportunities. In a LinkedIn post , she thanked the company’s research and regulatory teams, writing that “every experiment run, every setback pushed through, and every breakthrough achieved reflects the very best of what science, and humanity, could and should do.” She has been replaced by Robert Walker , who was previously Novavax’s CMO. Walker had a brief stint at Meissa Vaccines before joining Novavax in 2022. He spent more than seven years at BARDA, a government agency tasked with financing and advancing early-stage biodefense projects, particularly preparing against pathogens and pandemics. → A spokesperson for Madrigal Pharmaceuticals tells Peer Review that the Rezdiffra maker has selected Ricardo Rocha as global head of medical affairs. Rocha had led the medical affairs team at Intellia Therapeutics since 2022 and served in numerous roles over a 19-year period at Novartis , including head of the cardiorenal & metabolism medical unit and regional medical head for the Latin America and Canada region. Looking to establish itself as the dominant force in the MASH field, Madrigal paid $60 million upfront in February for access to six siRNA candidates from Suzhou Ribo Life Science . → Sagimet Biosciences has a new medical chief. Eduardo Bruno Martins retired on Monday as Andreas Grauer takes on medical leadership at the metabolic and fibrosis company. Grauer previously held the same post at Omeros , Federation Bio and Corcept Therapeutics . Grauer joins Sagimet as the California biotech puts together the final touches on a Phase 2 study in MASH for the second half of this year. Its partner Ascletis has an acne treatment under regulatory review in China. → Edward Conner is leaping from company to company at a feverish pace, landing at Paragon ’s autoimmune spinoff Jade Biosciences for his fourth CMO job in five years. Conner left Astellas Gene Therapies in 2021 to become CMO of Locanabio , and a year later he was off to Third Harmonic Bio in the same role. After Third Harmonic shut down last year, Conner was named CMO of Ardelyx in August. Atara Biotherapeutics vet Rajani Dinavahi just replaced him at Ardelyx this month. A crew from Chinook Therapeutics started Jade after selling itself to Novartis and took the place of Aerovate Therapeutics on the Nasdaq. → NovaBridge Biosciences , which you may remember from its days as I-Mab , has tapped Mark Hagler as president and chief commercial officer. Hagler was elevated to commercial chief during a 10-year career at Sun Pharma , and he’s also been head of oncology marketing for Ipsen . NovaBridge has two bispecific antibodies in mid-stage development: givastomig (Claudin18.2×4-1BB) and VIS-101 (VEGF-AxANG-2). → Radius Health CFO and head of operations Bethany Sensenig has stepped down after Radius merged with Paratek Pharmaceuticals . On April 15, the Biogen vet also picked up a seat on the board of directors at Vancouver-based neuro biotech Alpha Cognition . You can also find her in the boardrooms at Ekterly maker KalVista Pharmaceuticals and Supernus Pharmaceuticals . → Christy Shafer will prepare Neurogene for the potential launch of its Rett syndrome gene therapy NGN-401 as chief commercial officer. Neurogene also said that president and CFO Christine Mikail has joined the board of directors. Shafer caught the attention of Peer Review in 2020, when she was named chief commercial officer at Marinus Pharmaceuticals . In March 2025, she became general manager, North America for Avidity Biosciences , the RNA specialist that Novartis bought for $12 billion. In November 2024, early results for NGN-401 were marred by the death of a Rett syndrome patient. → We have two new execs to discuss at Copenhagen-based MinervaX , which is developing a vaccine for group B Streptococcus : Chief development officer Jamila Louahed was global head of therapeutic vaccines R&D during a long career at GSK , and finance chief Hans Henrik Chrois Christensen spent six years with ImCheck Therapeutics as CFO and COO. Ipsen acquired ImCheck late last year for €350 million upfront. And while we’re thinking of ImCheck, its former CEO Pierre d’Epenoux is the newest board member at French neuropsychiatry biotech Elkedonia . → Dutch protein degradation shop Laigo Bio has welcomed Richard Sainson as CSO. Sainson worked at Paris-based Advesya in the same capacity from 2023-25, and he was VP of translational development for F-star Therapeutics . Hans Clevers , the former head of Roche ’s pharma research and early development (pRED) organization, leads a trio of additions to Laigo Bio’s scientific advisory board. → Felecia Ettenberg has replaced Elizabeth Grammer as chief legal officer at Ardelyx. Ettenberg held numerous roles over a 25-year career with Bristol Myers, including deputy general counsel, pipeline to patient global law. Grammer jumped to the Ardelyx team full time in 2012 and sits on the board at Sagimet Biosciences. → The next phase of Andrew Chan ’s career is starting to take shape, first as a venture partner at The Column Group and now as the new addition to the board of directors at Corvus Pharmaceuticals . Chan finished a 15-year run at Genentech as SVP, research biology, and spent more than two decades with the company overall. Corvus’ shares $CRVS soared in January after its Phase 1 readout for soquelitinib in severe atopic dermatitis. Endpoints is fielding the next Biopharma Sentiment Index (BPSI) — a concise, three-minute survey that distills thousands of industry views into a clear quarterly benchmark. This year is pivotal for biopharma, and we need your perspective on where things are going. Take the survey here.